Chapter 1

Business and Thesis

Molina Healthcare collects fixed monthly premiums from governments to run health plans for roughly 5.5 million low-income and elderly Americans, keeping the thin spread between those premiums and the medical claims it pays. Revenue has tripled since 2020, to $45.4 billion. But in 2025 the spread compressed sharply: the medical care ratio jumped to 91.7%, net income halved to $472 million, and the stock fell more than 60% from its peak. Everything that follows examines whether that break is temporary.

What Molina is

Molina is a pure-play government managed-care company. It contracts with state Medicaid agencies, with the federal Medicare program, and with the Affordable Care Act insurance marketplaces to arrange health care for people enrolled in those programs, operating across 21 states with about 5.5 million members at the end of 2025 [1]. It sells nothing to consumers directly and takes no commercial-employer risk; its customers are governments, and its revenue is other people's health-care budgets.

The business is heavily weighted to Medicaid, the joint federal-state program for low-income families. Medicaid supplied $32.2 billion of 2025 premium revenue against $6.2 billion from Medicare and $4.5 billion from the marketplaces — roughly three of every four premium dollars come from state Medicaid contracts [2].

Source: FY2025 Form 10-K segment revenue disclosures [3].

How it makes money

The economics are simple to state and hard to run. A state pays Molina a fixed per-member, per-month (PMPM) rate, set annually and required to be actuarially sound; in return, Molina assumes the medical and administrative cost risk for those members [4]. Molina keeps whatever premium is left after paying claims and running the plan. Because premiums are fixed by contract for the year while medical costs are not, the margin is set almost entirely by one ratio — the share of each premium dollar consumed by medical claims. Molina calls it the medical care ratio (MCR); the rest of the industry calls it the medical loss ratio. In Molina's own words, if premiums do not rise as fast as medical costs and utilization, "our medical margins will be compressed or eliminated, and our earnings will be negatively affected" [5].

The arithmetic leaves little room. In 2025, medical claims took 91.7 cents of every premium dollar and general and administrative costs took another 6.6 cents, leaving an operating margin under 2% and a net margin near 1% [6]. This is a business that converts $45 billion of revenue into roughly $0.5 billion of net profit by design — a low-margin, high-volume premium aggregator whose returns come from scale and cost control, not pricing power.

Source: FY2025 Form 10-K financial highlights; MCR is medical costs as a percentage of premium revenue [7].

Five years of growth, then a profit round-trip

Revenue tripled between 2020 and 2025, from $19.4 billion to $45.4 billion [8]. Almost none of that came from adding members organically — the count rose only from about 4.0 million to 5.5 million — and most came from acquisitions, state contract wins, higher-acuity membership, and rate increases. The 2025 growth alone leaned on the ConnectiCare acquisition, Medicaid rate increases, and marketplace expansion [9].

Profit did not follow the same line. Net income climbed toward $1.2 billion by 2024, then fell back to $472 million in 2025 — below where it stood in 2020 on more than double the revenue [10].

Source: revenue and net income as reported in FY2021 and FY2025 Form 10-Ks; 2020–2021 [11], 2024–2025 [12].

What went wrong in 2025

The divergence is the medical care ratio. It held near 88% for four straight years — a level Molina describes as its long-term target — before edging to 89.1% in 2024 and then jumping to 91.7% in 2025, a 260-basis-point move [13]. On roughly $43 billion of premium, each point of MCR is worth about $430 million of pre-tax margin, so the two-and-a-half point move explains most of the profit collapse. Molina attributes it to medical cost trend and utilization running higher than expected, plus acuity shifts in its membership as post-pandemic Medicaid eligibility redeterminations removed healthier members [14].

Source: consolidated MCR as reported; 2020–2021 [15], 2024–2025 [16]; 2022–2023 from the respective 10-Ks.

Management's read is that this is a rate problem, not a demand problem. On the July 2025 call, chief executive Joseph Zubretsky called the pressure "a temporary dislocation between premium rates and medical cost trend," adding that "nothing has changed our outlook for the long-term performance of the business" [17]. The logic: because state and federal rates reset annually and lag the cost trend, an acceleration in claims first compresses margin and later gets repriced into the next year's premiums. The counter-case is that the redetermination-era acuity shift is a level change in who Molina insures, not a timing gap that reprices away. The four-year stability at 88% and the isolated 2025 spike are consistent with the first reading; whether the ratio returns toward 88% or settles higher is the question later chapters test.

What the stock did

The market treated 2025 as more than a one-year miss. Molina traded above $400 in early 2024 and near $355 as late as April 2025, then fell to an intraday low around $123 in early 2026 — a drawdown of more than 65% — before recovering to about $225 by mid-July 2026. The decline in market value has been far larger, in percentage terms, than the decline in reported earnings, which is the kind of gap that draws value investors to look closer.

Source: NYSE market data, year-end closing prices; 2026 value is the close on 16 July 2026 (as reported).

The through-line this report answers

Molina is a low-margin aggregator of government-funded health plans that has tripled its revenue in five years, carries a net-cash balance sheet, and has just posted its worst medical margin in at least six years while its stock has more than halved.

That question has three parts, and each is a claim to be tested rather than assumed. The first is durability of the top line: whether a Medicaid-heavy revenue base is more or less reliable a decade out than it looks today, given how much of it rides on annual state appropriations and periodic contract rebids. The second is the margin: whether 91.7% is a cyclical peak that reprices back toward 88%, or a new floor. The third is cash: Molina's reported operating cash flow has swung from a $2.1 billion inflow to a $535 million outflow across these same years, driven by the timing of government receivables and payables rather than by the underlying economics [18] — a pattern that a cash-focused investor cannot take at face value and that a later chapter unpacks in full.

On the evidence so far, the growth question looks the most answerable in Molina's favor and the margin question the most genuinely open. What would change that read is straightforward to name: evidence that the 2025 acuity shift is permanent, or that state rates are structurally lagging cost trend rather than catching up, would move the margin from cyclical to structural — and with it, the whole case.